Second Generation Inhibitors of HIV-1 Maturation

ACS Medicinal Chemistry Letters
2019.0

Abstract

The strategy and tactics subtending the discovery and development of the second generation HIV-1 maturation inhibitor GSK-3532795/BMS-955176, a compound that exhibits a broader spectrum of antiviral effect in vitro and in clinical studies than the prototypical maturation inhibitor bevirimat, are described.

Knowledge Graph

Similar Paper

Second Generation Inhibitors of HIV-1 Maturation
ACS Medicinal Chemistry Letters 2019.0
Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation Inhibitors
Journal of Medicinal Chemistry 2012.0
Anti-AIDS Agents 81. Design, Synthesis, and Structure−Activity Relationship Study of Betulinic Acid and Moronic Acid Derivatives as Potent HIV Maturation Inhibitors
Journal of Medicinal Chemistry 2010.0
New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation
Antimicrobial Agents and Chemotherapy 2009.0
The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral
Antimicrobial Agents and Chemotherapy 2008.0
Anti-AIDS Agents. 78. Design, Synthesis, Metabolic Stability Assessment, and Antiviral Evaluation of Novel Betulinic Acid Derivatives as Potent Anti-Human Immunodeficiency Virus (HIV) Agents
Journal of Medicinal Chemistry 2009.0
Betulinic Acid Derivatives as Human Immunodeficiency Virus Type 2 (HIV-2) Inhibitors
Journal of Medicinal Chemistry 2009.0
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385
Bioorganic & Medicinal Chemistry Letters 2006.0
Anti-AIDS agents 73: Structure–activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl-betulinic acid derivatives
Bioorganic & Medicinal Chemistry Letters 2007.0
HIV-1 protease inhibitory activity of L-694,746, a novel metabolite of L-689,502
Biochemical and Biophysical Research Communications 1991.0